News

Company   ImmuPharma PLC
TIDM         IMM
Headline
Released    07:30 2-Jul-08
Number     0898Y07

FOR IMMEDIATE RELEASE

London, 2 July 2008

Long term toxicology studies confirmed the safety of Lupuzor^TM

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today Lupuzor^TM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.

For further information please contact:

ImmuPharma PLC

Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Dr Robert Zimmer, President & Chief Scientific Officer      + 33 389 32 7650
Richard Warr, Chairman                                                +44 20 7152 4080

Buchanan Communications +44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Panmure Gordon & Co +44 151 243 0963

Andrew Burnett


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Released 07:30 2-Jul-08 Number 0898Y07 FOR IMMEDIATE RELEASE London, 2 July 2008 Long term toxicology studies confirmed the safety of Lupuzor^TM ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces today Lupuzor^TM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme. For further information please contact: ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 7650 Richard Warr, Chairman +44 20 7152 4080 Buchanan Communications +44 20 7466 5000 Lisa Baderoon Rebecca Skye-Dietrich Panmure Gordon & Co +44 151 243 0963 Andrew Burnett ©2008 London Stock Exchange plc. All rights reserved